# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $59...
Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...
Financial Outlook for 2024The Company is reiterating its financial guidance for 2024, which was increased on June 6, 2024 as a ...
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of...
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target fr...